Axatilimab-csfr

🏢 公司概况 • 中文名称：因塞特医疗 Incyte Corporation • 主营业务：专注肿瘤、炎症、自身免疫疾病的创新生物制药 • 成立与上市：1991年成立，1993年纳斯达克上市 • 总部与员工：特拉华州威尔明顿，约2,617人 📦 核心产品 • 芦可替尼片：JAK1/2抑制剂，治疗骨髓纤维化/真性红细胞增多症，2024年销售额$27亿+ • 芦可替尼乳膏：JAK抑制剂，治疗特应性皮炎/白癜风，Q4销售额$2.07亿（+28%） • 肿瘤产品：MONJUVI、PEMAZYRE、ZYNYZ、NIKTIMVO等 💰 核心财务数据 • 收盘价/市值：95.9/190.9亿 • 市盈率：14.97倍 • EPS：6.47 • 2025Q4营收：15.1亿（+28%），全年51.4亿（+22%） • 52周区间：53.56-112.29 📊 盈利能力指标 • ROE：29.15% • ROA：17.5% • 2025净利润：12.9亿 | 营收：$51.4亿 • 毛利率：80%+ | 营业利润率：25% • 2026指引：营收47.7-49.4亿 🏛️ 商业模式 • 垂直整合创新药企：从靶点发现到商业化全产业链 • 核心收入：Jakafi稳定增长+Opzelura爆发增长+特许权使用费 • 研发驱动：14个关键临床试验，目标2030年推出10+产品 🛡️ 护城河 • JAK抑制剂技术壁垒：全球首个获批JAK1/2抑制剂，20+年研发经验 • 唯一获批优势：Jakafi是骨髓纤维化/真红唯一用药 • 丰富管线：4个潜在2025年获批产品 💡 投资逻辑 • Opzelura爆发潜力：白癜风市场巨大，HS适应症3期试验进行中 • Jakafi稳定现金流：适应症持续扩展，峰值有望超$35亿 • 肿瘤布局扩张：收购MorphoSys后产品组合大幅扩充 ⚠️ 风险提示 • 专利悬崖：Jakafi专利2028年到期，仿制药竞争威胁 • Opzelura指引低于预期：2026年营收指引$7.5-7.9亿，低于预期$8亿+ • 临床研发风险：3期试验存在失败不确定性 📌 免责声明 本文仅供参考，不构成任何投资建议。 #INCY #因塞特医疗 #美股 #生物制药 #JAK抑制剂 #创新药 #标普500 #皮肤病

Orca Bio has announced that the US FDA extended the review timeline for its Biologics License Application (BLA) for Orca-T, an investigational allogeneic T-cell immunotherapy targeting hematologic malignancies including acute leukemias and myelodysplastic syndromes. The revised PDUFA target action date is July 6, 2026, three months beyond the original deadline, following the FDA’s classification of a recent company submission as a Major Amendment to the BLA. The extension was triggered by Orca Bio’s submission of updated chemistry, manufacturing and controls (CMC) information provided in response to FDA requests during the standard review process, the company said. The agency has not requested additional clinical data, and Orca Bio stated it believes the updated CMC information does not affect the benefit-risk conclusions of the BLA. The filing carries Priority Review designation, and Orca-T has previously received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for the prevention of graft-versus-host disease (GVHD) or death in patients eligible for hematopoietic stem cell transplant (HSCT). Orca-T is composed of highly purified hematopoietic stem cells, regulatory T-cells, and conventional T-cells derived from matched related or unrelated donors. The inclusion of regulatory T-cells is central to the product’s design rationale: by modulating the post-transplant alloreactive immune response, the approach aims to reduce GVHD without eliminating the graft-versus-leukemia effect that makes allogeneic transplantation therapeutically relevant. This positions Orca-T not as an adjunctive drug but as a redefined graft — intended to replace conventional unmanipulated cell products at the transplant step itself. The clinical program supporting the BLA includes the Phase III Precision-T trial (NCT05316701), which enrolled patients with hematologic malignancies and used moderate or severe chronic GVHD-free survival at 12 months as its primary endpoint, assessed by an independent Endpoint Adjudication Committee. An earlier Phase Ib study (NCT04013685) focused on safety endpoints including the incidence of grade 3 or 4 acute GVHD and primary graft failure. The filing enters review at a time when GVHD remains a substantial source of morbidity and non-relapse mortality in the allogeneic transplant setting. Approved prophylactic agents include abatacept, which received FDA approval in 2021 for use in unrelated-donor transplants, while treatment options for established GVHD include ruxolitinib, belumosudil, and axatilimab, the latter approved in 2024 for recurrent or refractory chronic GVHD. Despite these additions, no approved intervention has demonstrated the capacity to simultaneously reduce GVHD and preserve the graft-versus-leukemia effect — the core biological tension that precision graft engineering approaches such as Orca-T are designed to address. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website